New drug combo shows promise for Tough-to-Treat lymphoma
NCT ID NCT02651662
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested two experimental drugs, odronextamab and cemiplimab, in 105 patients with aggressive B-cell lymphoma that had stopped responding to other treatments. The main goal was to check safety and find the best dose. Researchers also looked at how well the drugs worked and how the body processed them.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan, 49546, United States
-
Chaim Sheba Medical Center
Ramat Gan, 5265601, Israel
-
Copernicus Memorial Hospital
Lodz, 93-513, Poland
-
Dana Farber/Harvard Cancer Center - PO box 849168
Boston, Massachusetts, 02215, United States
-
Hadassah Medical Center
Jerusalem, 91200, Israel
-
Harvard Medical School - Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
-
Hospital Clinico Universitario de Salamanca
Salamanca, 37007, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, 39008.0, Spain
-
Hospital Universitario Puerta de Hierro - Majadahonda
Majadahonda, Madrid, 28222, Spain
-
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Madrid, 28223, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, 08041, Spain
-
Institut Catala dOncologia (ICO Hospitalet)
Barcelona, 08908, Spain
-
Johns Hopkins University
Baltimore, Maryland, 21205, United States
-
MD Anderson Cancer Center- Madrid
Madrid, 28033, Spain
-
Medical University Vienna
Vienna, 1190, Austria
-
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa
Warsaw, 02781, Poland
-
Pratia MCM Krakow
Krakow, Malopolska, 30-510, Poland
-
Pratia Onkologia Katowice
Katowice, 40-519, Poland
-
Soroka
Beersheba, 84101, Israel
-
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
-
Uniklinikum Salzburg (LKH) Universitatsklinik fur Innere Medizin III
Salzburg, 5020, Austria
-
Universitatsklinikum Jena
Jena, 7747, Germany
-
Universitatsklinikum Schleswig-Holstein, Campus Kiel
Kiel, 24105, Germany
-
University Hospital Frankfurt
Frankfurt am Main, 60590, Germany
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
Uniwersyteckie Centrum Kliniczne
Gdansk, Pomeranian Voivodeship, 80-952, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.